Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.49 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16825188 | 0.88 | TGFBR1 (0.56) | SLC2A1TGFBR1MEN1KMT2AALDH1A1 | |
| SCHEMBL30812262 | 0.87 | GPR119 (0.51) | TGFBR1GPR119 | |
| SCHEMBL4155287 | 0.86 | ALDH1A1 (0.59) | SLC2A1TGFBR1GPR119ALDH1A1 | |
| SCHEMBL13913655 | 0.85 | KDM4E (0.60) | GPR119 | |
| SCHEMBL4139485 | 0.83 | MGLL (0.53) | GPR119 | |
| SCHEMBL8703435 | 0.83 | TP53 (0.54) | — | |
| SCHEMBL13888078 | 0.82 | GPR119 (0.62) | SLC2A1GPR119SGMS1SGMS2 | |
| SCHEMBL3358948 | 0.82 | KDM4E (0.59) | GPR119ALDH1A1 | |
| SCHEMBL15591515 | 0.81 | MEN1 (0.54) | SLC2A1TGFBR1GPR119MEN1KMT2A | |
| SCHEMBL791915 | 0.81 | SLC2A1 (0.63) | SLC2A1TGFBR1GPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | SLC2A1 1362/4885TGFBR1 953/4885GPR119 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.